Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07609446 | Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma | not yet recruiting | — | 30 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07609706 | A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment | not yet recruiting | Phase 1 | 20 | GlaxoSmithKlineINDUSTRY | 0 | May 27, 2026 |
| clinicaltrials |
| NCT07600151 | Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma(CONQUISTADOR) | not yet recruiting | Phase 1 / Phase 2 | 220 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07585747 | A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide(CUREMZL002) | not yet recruiting | Phase 2 | 27 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07517705 | MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 2 | 50 | University of NebraskaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07583771 | A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma | not yet recruiting | Phase 1 | 186 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT07584850 | Evaluation of GI001 for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | not yet recruiting | Early Phase 1 | 9 | Ruijin HospitalOTHER | 0 | May 13, 2026 | clinicaltrials |
| NCT07582159 | Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | not yet recruiting | Phase 2 | 35 | City of Hope Medical CenterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07578077 | Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 58 | City of Hope Medical CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07569757 | Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma | not yet recruiting | Phase 3 | 260 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT07567014 | Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS | not yet recruiting | Phase 2 | 60 | NYU Langone HealthOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07569965 | Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL(FRONTIER) | not yet recruiting | Phase 2 | 52 | Miltenyi Biomedicine GmbHINDUSTRY | 0 | May 6, 2026 | clinicaltrials |
| NCT05728879 | Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution | not yet recruiting | Early Phase 1 | 30 | Northwestern UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07554482 | Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma | not yet recruiting | Phase 2 | 34 | Beijing Tongren HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07552324 | Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP | not yet recruiting | Phase 2 | 28 | Ruijin HospitalOTHER | 0 | Apr 27, 2026 | clinicaltrials |
| NCT07550855 | Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma(FLOURISH) | not yet recruiting | Phase 2 | 52 | Sun Yat-sen UniversityOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07542418 | Study of Thiotepa Combination With Melphalan (TM Protocol) Conditioning for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma：A Prospective Randomized Controlled Clinical Trial | not yet recruiting | N/A | 204 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 0 | Apr 21, 2026 | clinicaltrials |
| NCT07538960 | Epidemiology and Management of Cutaneous T-Cell Lymphoma at Hospital México, Costa Rica. | not yet recruiting | — | 350 | Caja Costarricense de Seguro SocialOTHER_GOV | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07539233 | A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma. | not yet recruiting | Early Phase 1 | 24 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07539688 | Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma | not yet recruiting | Phase 1 | 18 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Apr 20, 2026 | clinicaltrials |
| NCT07535710 | Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 37 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07535762 | Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma | not yet recruiting | Phase 2 | 36 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07537049 | BR101 in Patients With Relapsed/Refractory Multiple Myeloma | not yet recruiting | Phase 1 | 10 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07476105 | Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment | not yet recruiting | N/A | 170 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07529405 | A Study of VG712 in Patients With Mycosis Fungoides(CurbMF) | not yet recruiting | Phase 2 | 386 | Virogen Biotechnology Inc.INDUSTRY | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07525817 | A Real-World Study of Pirtobrutinib in cBTKi-Resistant/Intolerant Mature B-Cell Lymphoma | not yet recruiting | — | 40 | Ou Bai, MD/PHDOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07493330 | Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL | not yet recruiting | Phase 1 / Phase 2 | 86 | Ruijin HospitalOTHER | 0 | Apr 7, 2026 | clinicaltrials |
| NCT07511114 | A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping | not yet recruiting | Phase 3 | 156 | Ruijin HospitalOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07510100 | Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma(FUMANBA-04) | not yet recruiting | Phase 1 / Phase 2 | 17 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07221656 | Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration | not yet recruiting | — | 20 | Mayo ClinicOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07505849 | ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lymphoma | not yet recruiting | Phase 2 | 100 | KeshuZhouOTHER_GOV | 0 | Apr 1, 2026 | clinicaltrials |
| NCT07498920 | Gut Microbiome in DLBCL Treated With Glofitamab | not yet recruiting | — | 30 | Peking Union Medical College HospitalOTHER | 0 | Mar 27, 2026 | clinicaltrials |
| NCT07492407 | CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma | not yet recruiting | — | 131 | Henan Cancer HospitalOTHER_GOV | 0 | Mar 25, 2026 | clinicaltrials |
| NCT05969821 | Clonal Hematopoiesis of Immunological Significance(CHIS) | not yet recruiting | — | 5,000 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07482761 | Multiple Myeloma t(4 ;14) FFPE Samples(MM-t4-14-FFPE) | not yet recruiting | — | 20 | BIWAKOINDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07476027 | Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL | not yet recruiting | Early Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Mar 17, 2026 | clinicaltrials |
| NCT07476378 | A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies(Archonc-001) | not yet recruiting | N/A | 69 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07477366 | Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma | not yet recruiting | Phase 2 | 20 | ImmunityBio, Inc.INDUSTRY | 0 | Mar 17, 2026 | clinicaltrials |
| NCT07477769 | Lymphocyte Phenotype of Autosomal Recessive Congenital Ichthyoses Mutated NIPAL4 (Nipal4-nEDD)(NIPALYMPHO) | not yet recruiting | — | 10 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Mar 17, 2026 | clinicaltrials |
| NCT07474961 | BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.(BLOOD-dose) | not yet recruiting | Phase 4 | 400 | Anne Louise Tølbøll SørensenOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07463781 | Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy(NEURO_CAR-T) | not yet recruiting | — | 100 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07464210 | Nemtabrutinib, Bortezomib, and Rituximab for WM | not yet recruiting | Phase 2 | 19 | Seoul National University HospitalOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07457177 | Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL | not yet recruiting | Phase 2 | 40 | LIANG WANGOTHER | 0 | Mar 9, 2026 | clinicaltrials |
| NCT07458659 | Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma(CART-BCMA) | not yet recruiting | Early Phase 1 | 3 | Chulalongkorn UniversityOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07441954 | Pomalidomide Combined With Obinutuzumab in the Treatment of Patients With Relapsed/Refractory Indolent Lymphoma(GP-1) | not yet recruiting | Phase 1 / Phase 2 | 53 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Mar 2, 2026 | clinicaltrials |
| NCT07421856 | Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial. | not yet recruiting | Phase 1 / Phase 2 | 24 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 0 | Feb 19, 2026 | clinicaltrials |
| NCT07406230 | Methotrexate Early Toxicity Monitoring(METoxiM) | not yet recruiting | N/A | 50 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07407010 | BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM(CM336-001) | not yet recruiting | Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Feb 12, 2026 | clinicaltrials |
| NCT07403071 | Validating Fish Oil's Role in Alleviating Bortezomib-Induced Neuropathy: A Multi-Method Study Integrating Big Data, Experimental, and Clinical Research | not yet recruiting | — | 200 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Feb 11, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 27, 2026source: clinicaltrials